Chinese english Germany Japanese Korea

CHIR-124

CHIR-124 Struktur
405168-58-3
CAS-Nr.
405168-58-3
Englisch Name:
CHIR-124
Synonyma:
CS-2141;CHIR-124;CHIR-124 USP/EP/BP;CHIR-124 (CHIR124;4-[((3S)-1-Azabicyclo[2.2.2]oct-3-yl)amino]-3-(1H-benzimidazol-2-yl)-6-chloroquinolin-2(1H)-one;2(1H)-Quinolinone, 4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylaMino]-3-(1H-benziMidazol-2-yl)-6-chloro-;Platelet-derived growth factor receptor,PDGFR,CHIR-124,Checkpoint Kinase (Chk),CD135,Fms like tyrosine kinase 3,Cluster of differentiation antigen 135,inhibit,Apoptosis,Inhibitor,FLT3
CBNumber:
CB32561465
Summenformel:
C23H22ClN5O
Molgewicht:
419.91
MOL-Datei:
405168-58-3.mol
Request For Quotation

CHIR-124 Eigenschaften

Dichte
1.46
storage temp. 
Store at -20°C
Löslichkeit
insoluble in H2O; ≥10.5 mg/mL in DMSO; ≥2.61 mg/mL in EtOH with gentle warming
Aggregatzustand
solid
pka
9.00±0.70(Predicted)
Sicherheit
  • Risiko- und Sicherheitserklärung
  • Gefahreninformationscode (GHS)
Bildanzeige (GHS) GHS hazard pictograms
Alarmwort Warnung
Gefahrenhinweise
Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code
H302 Gesundheitsschädlich bei Verschlucken. Akute Toxizität oral Kategorie 4 Warnung GHS hazard pictogramssrc="/GHS07.jpg" width="20" height="20" /> P264, P270, P301+P312, P330, P501
Sicherheit
P280 Schutzhandschuhe/Schutzkleidung/Augenschutz tragen.
P305+P351+P338 BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach Möglichkeit entfernen. Weiter spülen.

CHIR-124 Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Checkpoint kinase 1 (Chk1) regulates S and G2-M phase cell cycle checkpoints in response to DNA damage. CHIR124 is a cell-permeable, quinolone-based inhibitor of Chk1 (IC50 = 0.3 nM in vitro). It demonstrates high selectivity for Chk1 by displaying inhibitory values 2,000-fold higher against Chk2 (IC50 = 0.7 μM). In synergy with topoisomerase I poisons or ionizing radiation, CHIR124 can inhibit the growth of p53-mutant solid tumor cells both in vitro and in a xenograft model, potentiating tumor apoptosis.

Verwenden

CHIR 124 is a cell-permeable molecule with a quinolone-based structure. It inhibits checkpoint kinase 1 (Chk1) which regulates S and G2-M cekk cycle checkpoints in response to DNA damage. Application towards inhibition of tumor cell growth.

CHIR-124 Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

CHIR-124 Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 80)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
Hubei xin bonus chemical co. LTD 		86-13657291602
linda@hubeijusheng.com CHINA 22968 58
career henan chemical co 		+86-0371-86658258 15093356674;
 factory@coreychem.com China 29826 58
Dideu Industries Group Limited 		+86-29-89586680 +86-15129568250
 1026@dideu.com China 29016 58
Zhejiang J&C Biological Technology Co.,Limited 		+1-2135480471 +1-2135480471
 sales@sarms4muscle.com China 10523 58
InvivoChem 		+1-708-310-1919 +1-13798911105
 sales@invivochem.cn United States 6393 58
TargetMol Chemicals Inc. 		+1-781-999-5354
support@targetmol.com United States 19973 58
Wuhan Topule Biopharmaceutical Co., Ltd 		+8618327326525
 masar@topule.com China 8474 58
LEAPCHEM CO., LTD. 		+86-852-30606658
market18@leapchem.com China 43348 58
Aladdin Scientific 		+1-833-552-7181
sales@aladdinsci.com United States 52927 58
Shanghai Boyle Chemical Co., Ltd.
sales@boylechem.com China 2923 55

405168-58-3()Verwandte Suche:

5-Amino-1H-triazolo[4,5-d]pyrimidin-7-ol
  • CHIR-124
  • 2(1H)-Quinolinone, 4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylaMino]-3-(1H-benziMidazol-2-yl)-6-chloro-
  • 4-[((3S)-1-Azabicyclo[2.2.2]oct-3-yl)amino]-3-(1H-benzimidazol-2-yl)-6-chloroquinolin-2(1H)-one
  • CS-2141
  • CHIR-124 (CHIR124
  • CHIR-124 USP/EP/BP
  • Platelet-derived growth factor receptor,PDGFR,CHIR-124,Checkpoint Kinase (Chk),CD135,Fms like tyrosine kinase 3,Cluster of differentiation antigen 135,inhibit,Apoptosis,Inhibitor,FLT3
  • 405168-58-3
  • Inhibitors
Copyright 2019 © ChemicalBook. All rights reserved